Core Viewpoint - Inhibrx Biosciences, Inc. is making significant strides in developing its oncology pipeline, particularly with drugs INBRX-109 and INBRX-106, following the sale of INBRX-101 to Sanofi for $2.2 billion, which has generated shareholder value and interest in the company's future prospects [1][2][16]. Company Developments - Inhibrx has advanced INBRX-101 into a phase 3 study for alpha-1 antitrypsin deficiency, attracting attention from Sanofi, which acquired the drug for an aggregate value of $2.2 billion [1][2][16]. - The company has retained rights to its oncology pipeline, focusing on two key compounds: INBRX-109 for Ewing Sarcoma and INBRX-106 for multiple solid tumor types [3][26]. Drug Pipeline - INBRX-109 is a tetravalent molecule targeting Death receptor 5 (DR5) and is being developed for Ewing Sarcoma, a rare tumor primarily affecting children and young adults [4][5]. - The Ewing Sarcoma therapeutics market is projected to reach $424.42 million by 2032, indicating a moderate market opportunity for INBRX-109 [6]. - INBRX-106 is a hexavalent molecule targeting OX40, with potential applications across various solid tumor types, including non-small cell lung cancer and melanoma [11][12]. Clinical Trials and Efficacy - A phase 1 study for INBRX-109 has been initiated, aiming to recruit 240 patients to evaluate its efficacy in combination with standard care therapies [7][8]. - The combination of INBRX-109 with standard chemotherapeutics IRI and TMZ has shown an objective response rate (ORR) of 53.8%, with classical Ewing Sarcoma patients achieving an ORR of 71.4% [9][10][26]. - INBRX-106 has demonstrated improved antitumor activity in preclinical models, leading to its advancement into phase 1 studies in combination with Keytruda [15][27]. Financial Position - Following the sale of INBRX-101, Inhibrx has $30 per share in cash and a contingent value right for an additional $5 upon achieving regulatory milestones [18][16]. - The company reported cash and cash equivalents of $277.9 million as of December 31, 2023, with a cash burn rate of approximately $89.9 million per quarter, indicating a need for future funding [20][21].

SAN DIEGO, May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT") augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency ("AATD"). Immediately prior to the closing of the mer ...

SAN DIEGO, May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"), the Nasdaq Global Market ("Nasdaq") informed the Company that Nasdaq intends to permit the commencement of the trading of the shares of SpinCo ...

About Inhibrx, Inc. Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. For more information, please visit www.inhibrx.com. Exhibit 99.1 Inhibrx Reports First Quarter 2024 Financial Results and Recent Corpora ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or or ...

SAN DIEGO, May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. ("SpinCo"), to holders of shares of the Company's common stock on a pro rata basis (the "Spin-Off"). The Company also announced that the distribution in the Spin-Off is expected to occur at 11:59 p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiza ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or org ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or or ...